Sodium thiosulfate - Fennec Pharmaceuticals
Alternative Names: PEDMARK; PEDMARQSI; Sodium hyposulfite; STS - FennecLatest Information Update: 01 Jun 2025
At a glance
- Originator Oregon Health & Science University
- Developer Fennec Pharmaceuticals
- Class Antidotes; Antituberculars; Chemoprotectants; Thiosulfates; Vasodilators
- Mechanism of Action Antioxidants; Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Sensorineural hearing loss
Most Recent Events
- 31 May 2025 The Scottish Medicines Consortium (SMC) accepts PEDMARQSI® for use in Scotland
- 13 May 2025 PEDMARQSI receives Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection (Prior to May 2025)
- 13 May 2025 The National Comprehensive Cancer Network, or NCCN, recommends PEDMARK for the AYA population with a 2A endorsement